Researchers at Mayo Clinic's campus in Jacksonville and Virginia Tech in Blacksburg, Va., through their technology commercialization efforts, have licensed compounds to AstraZeneca for potential new drug therapies to treat depression. The collaboration advances both the development of novel compounds and supports ongoing research by Mayo and Virginia Tech in the area of triple reuptake inhibitors.

Read More: Mayo Invention Collaboration Focuses on New Treatment For Depression